X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4923) 4923
Publication (671) 671
Book Review (12) 12
Conference Proceeding (8) 8
Book Chapter (4) 4
Book / eBook (3) 3
Dissertation (2) 2
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azacitidine - pharmacology (4351) 4351
humans (3504) 3504
azacitidine - analogs & derivatives (2542) 2542
dna methylation (2331) 2331
index medicus (2051) 2051
animals (1811) 1811
methylation (1628) 1628
oncology (1487) 1487
cell line, tumor (1396) 1396
female (1293) 1293
dna methylation - drug effects (1136) 1136
male (1111) 1111
mice (1036) 1036
cancer (887) 887
expression (886) 886
promoter regions, genetic (802) 802
antimetabolites, antineoplastic - pharmacology (743) 743
enzyme inhibitors - pharmacology (700) 700
biochemistry & molecular biology (665) 665
gene expression (653) 653
decitabine (617) 617
gene expression regulation, neoplastic - drug effects (609) 609
cell biology (601) 601
middle aged (570) 570
epigenetics (563) 563
cell line (558) 558
hydroxamic acids - pharmacology (534) 534
dna (528) 528
reverse transcriptase polymerase chain reaction (509) 509
cpg islands (506) 506
aged (503) 503
tumor cells, cultured (496) 496
cells, cultured (490) 490
gene expression regulation, neoplastic (469) 469
dna modification methylases - antagonists & inhibitors (466) 466
genes (466) 466
adult (464) 464
rna, messenger - metabolism (440) 440
5-azacytidine (438) 438
apoptosis (434) 434
genetic aspects (434) 434
epigenesis, genetic (428) 428
gene-expression (428) 428
gene silencing (421) 421
base sequence (419) 419
research (409) 409
rna, messenger - genetics (409) 409
gene (399) 399
azacitidine - therapeutic use (397) 397
promoter regions, genetic - genetics (392) 392
5-aza-2'-deoxycytidine (373) 373
genetics & heredity (367) 367
hematology (366) 366
analysis (358) 358
cell proliferation - drug effects (348) 348
rats (345) 345
differentiation (341) 341
molecular sequence data (326) 326
research article (323) 323
pharmacology & pharmacy (320) 320
antineoplastic agents - pharmacology (318) 318
cell differentiation - drug effects (316) 316
cells (316) 316
hypermethylation (312) 312
apoptosis - drug effects (310) 310
down-regulation (306) 306
proteins (306) 306
deoxyribonucleic acid--dna (296) 296
gene expression regulation - drug effects (291) 291
article (284) 284
tumors (277) 277
histones - metabolism (276) 276
dose-response relationship, drug (274) 274
azacitidine (273) 273
mutation (268) 268
epigenesis, genetic - drug effects (259) 259
demethylation (253) 253
azacitidine - administration & dosage (252) 252
dna - metabolism (250) 250
blotting, western (249) 249
transfection (243) 243
cpg islands - genetics (238) 238
time factors (236) 236
aged, 80 and over (233) 233
polymerase chain reaction (233) 233
dna-methyltransferases - metabolism (232) 232
neoplasm proteins - genetics (225) 225
transcription (224) 224
leukemia (222) 222
activation (220) 220
acute myeloid-leukemia (220) 220
histone deacetylase inhibitors (219) 219
medicine, research & experimental (209) 209
dna methylation - genetics (207) 207
cell proliferation (204) 204
carcinoma (203) 203
dna-methyltransferases - antagonists & inhibitors (202) 202
promoter (200) 200
myelodysplastic syndromes - drug therapy (197) 197
phenotype (192) 192
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4757) 4757
Chinese (118) 118
Russian (32) 32
German (5) 5
Japanese (5) 5
Spanish (5) 5
French (3) 3
Slovak (3) 3
Czech (1) 1
Italian (1) 1
Polish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Seminars in Hematology, ISSN 0037-1963, 2005, Volume 42, Issue 2, pp. S9 - S16
Journal Article
International Journal of Cancer, ISSN 0020-7136, 08/2008, Volume 123, Issue 3, pp. 552 - 560
Genistein is a phytoestrogen that has been reported to suppress the AKT signaling pathway in several malignancies. However, the molecular mechanism of... 
Prostate cancer | Genistein | Tumor suppressor gene | APOPTOSIS | METHYLATION | PROTEIN-KINASE | TRANSCRIPTION | SIRT1 | FACULTATIVE HETEROCHROMATIN | CYLD | prostate cancer | genistein | ONCOLOGY | SIGNALING PATHWAY | NF-KAPPA-B | EXPRESSION | tumor suppressor gene | PTEN Phosphohydrolase - drug effects | Prostatic Neoplasms - metabolism | Deubiquitinating Enzyme CYLD | CpG Islands - drug effects | Humans | Male | NF-kappa B - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Genes, Tumor Suppressor - drug effects | Genes, p53 - drug effects | Prostatic Neoplasms - genetics | Chromatin Immunoprecipitation | Forkhead Transcription Factors - metabolism | Sirtuin 1 | Antimetabolites, Antineoplastic - pharmacology | Electrophoretic Mobility Shift Assay | Gene Expression Regulation, Neoplastic - drug effects | Chromones - pharmacology | Anticarcinogenic Agents - pharmacology | Hydroxamic Acids - pharmacology | Phytoestrogens - pharmacology | Prostatic Neoplasms - drug therapy | PTEN Phosphohydrolase - genetics | Tumor Suppressor Proteins - metabolism | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | PTEN Phosphohydrolase - metabolism | Azacitidine - analogs & derivatives | Down-Regulation - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Histones - drug effects | Gene Expression Regulation - drug effects | Up-Regulation - drug effects | Azacitidine - pharmacology | Acetylation - drug effects | Methylation - drug effects | Genistein - pharmacology | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Histones - metabolism | Forkhead Box Protein O3 | Sirtuins - metabolism | NF-kappa B - drug effects | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2002, Volume 86, Issue 10, pp. 1652 - 1657
Journal Article
Molecular Cancer, ISSN 1476-4598, 02/2013, Volume 12, Issue 1, pp. 9 - 9
Background: Estrogen receptor-alpha (ER alpha)-negative breast cancer is clinically aggressive and normally does not respond to conventional estrogen... 
Breast cancer | Epigenetic | Tamoxifen | ERα | Genistein | CELLS | HISTONE DEACETYLASE INHIBITOR | METHYLATION | ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | TRICHOSTATIN-A | IN-VITRO | ONCOLOGY | GROWTH | GENES | EXPRESSION | ER alpha | Gene Expression - drug effects | Humans | Tamoxifen - administration & dosage | DNA (Cytosine-5-)-Methyltransferases - metabolism | Anticarcinogenic Agents - administration & dosage | Estrogen Receptor alpha - metabolism | Female | Genistein - administration & dosage | Epigenesis, Genetic - drug effects | Anticarcinogenic Agents - pharmacology | Hydroxamic Acids - pharmacology | Estradiol - pharmacology | Cell Survival - drug effects | Promoter Regions, Genetic | Antineoplastic Agents, Hormonal - pharmacology | DNA (Cytosine-5-)-Methyltransferase 1 | Antineoplastic Agents, Hormonal - administration & dosage | Azacitidine - analogs & derivatives | Mice, Transgenic | Breast Neoplasms - drug therapy | Breast Neoplasms - prevention & control | Drug Synergism | Xenograft Model Antitumor Assays | Azacitidine - pharmacology | Animals | Estrogen Receptor alpha - genetics | Tumor Burden - drug effects | Breast Neoplasms - pathology | Mice, Nude | Genistein - pharmacology | Tamoxifen - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Mice | Histones - metabolism | Proliferating Cell Nuclear Antigen - metabolism | Drug Resistance, Neoplasm - drug effects | Histone Deacetylase 1 - metabolism
Journal Article
Circulation Research: Journal of the American Heart Association, ISSN 0009-7330, 09/2002, Volume 91, Issue 6, pp. 501 - 508
Journal Article
Leukemia, ISSN 0887-6924, 2014, Volume 28, Issue 8, pp. 1657 - 1665
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2005, Volume 4, Issue 10, pp. 1515 - 1520
Journal Article
Cell Death and Disease, ISSN 2041-4889, 09/2013, Volume 4, Issue 9, pp. e798 - e798
Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of... 
Extrinsic apoptosis | DNA methylation | Histone deacetylase inhibitors | Intrinsic apoptosis | Multiple myeloma | HDAC INHIBITORS | multiple myeloma | intrinsic apoptosis | BH3 MIMETIC ABT-737 | ANTITUMOR ACTIVITIES | TRAIL RECEPTOR AGONIST | extrinsic apoptosis | CELL-DEATH | CELL BIOLOGY | MURINE MODEL | APOPTOSIS-INDUCING LIGAND | MOUSE MODEL | CHEMOTHERAPEUTIC-AGENT | RESISTANCE | histone deacetylase inhibitors | Apoptosis - drug effects | Humans | Recombinant Proteins | Biphenyl Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Death Domain - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Multiple Myeloma - drug therapy | TNF-Related Apoptosis-Inducing Ligand - pharmacology | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Nitrophenols - therapeutic use | Indoles - pharmacology | Hydroxamic Acids - pharmacology | Mice, Inbred C57BL | Mice, Transgenic | Piperazines - therapeutic use | Multiple Myeloma - metabolism | Sulfonamides - pharmacology | Piperazines - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | TNF-Related Apoptosis-Inducing Ligand - therapeutic use | Azacitidine - pharmacology | Multiple Myeloma - pathology | Animals | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Mice | Azacitidine - therapeutic use | Drug Screening Assays, Antitumor | Original
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 7/2010, Volume 70, Issue 11, pp. 1381 - 1394
The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Myelodysplastic- syndromes, treatment | Lenalidomide, therapeutic use | Research-and-development | Erythropoietins, therapeutic use | Decitabine, therapeutic use | Romiplostim, therapeutic use | Histone-deacetylase- inhibitors, therapeutic use | Azacitidine, therapeutic use | Darbepoetin-alfa, therapeutic use | Farnesyl-transferase-inhibitors, therapeutic use | Antithymocyte-globulin, therapeutic use | Deferasirox, therapeutic use | Granulocyte-colony-stimulating-factors, therapeutic use | Clofarabine, therapeutic use | Deferoxamine, therapeutic use | LOW-RISK | COLONY-STIMULATING FACTOR | RESPONSE CRITERIA | PHASE-II | ANTITHYMOCYTE GLOBULIN | PHARMACOLOGY & PHARMACY | VALPROIC ACID | TOXICOLOGY | ACUTE MYELOID-LEUKEMIA | INTERMEDIATE-RISK | INTERNATIONAL WORKING GROUP | DARBEPOETIN-ALPHA | Drugs, Investigational - pharmacology | Recombinant Fusion Proteins - pharmacology | Adenine Nucleotides - pharmacology | Humans | Immunosuppressive Agents - therapeutic use | Recombinant Fusion Proteins - therapeutic use | Drugs, Investigational - therapeutic use | Thrombopoietin - therapeutic use | Thalidomide - pharmacology | Receptors, Fc - therapeutic use | Thalidomide - analogs & derivatives | Anemia - drug therapy | Farnesyltranstransferase - antagonists & inhibitors | Immunosuppressive Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Bone Marrow - physiopathology | Iron Chelating Agents - therapeutic use | Risk Factors | Arabinonucleosides - pharmacology | Adenine Nucleotides - therapeutic use | Farnesyltranstransferase - therapeutic use | Piperazines - therapeutic use | Thrombopoietin - pharmacology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Arabinonucleosides - therapeutic use | Farnesyltranstransferase - pharmacology | Iron Chelating Agents - pharmacology | Pyrimidines - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Histone Deacetylase Inhibitors - therapeutic use | Benzamides | Thalidomide - therapeutic use | DNA Methylation - drug effects | Antimitotic agents | Care and treatment | Prognosis | Dosage and administration | Research | Antineoplastic agents | Myelodysplastic syndromes
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 06/2013, Volume 14, Issue 1, pp. 32 - 32
Background: Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to high RNA synthesis, including synthesis of... 
Dormancy | Leukemia | RNA polymerase II inhibitors | PROGENITOR CELLS | CYTOSINE-ARABINOSIDE | COLONY-STIMULATING FACTOR | TRANSCRIPTION | DOWN-REGULATION | MYELOBLASTIC-LEUKEMIA | P-GLYCOPROTEIN | R-ROSCOVITINE | HEMATOPOIETIC STEM-CELLS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | FLAVOPIRIDOL | Cytarabine - pharmacology | TOR Serine-Threonine Kinases - metabolism | Adenine Nucleotides - pharmacology | Apoptosis - drug effects | Humans | Leukemia, Myeloid - genetics | Daunorubicin - pharmacology | RNA Polymerase II - metabolism | RNA, Neoplasm - metabolism | Heterocyclic Compounds, 4 or More Rings - pharmacology | Dose-Response Relationship, Drug | Leukemia, Myeloid - pathology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Piperidines - pharmacology | Antineoplastic Agents - pharmacology | Flavonoids - pharmacology | Cell Survival - drug effects | Acute Disease | RNA Polymerase II - antagonists & inhibitors | Purines - pharmacology | Enzyme Inhibitors - pharmacology | Etoposide - pharmacology | Arabinonucleosides - pharmacology | Sirolimus - pharmacology | Azacitidine - pharmacology | Leukemia, Myeloid - metabolism | Cell Line, Tumor | RNA, Neoplasm - genetics | Anthracyclines | Synthesis | RNA | Heterocyclic compounds | Analysis | Physiological aspects | Etoposide | Apoptosis | DNA | Nucleosides | Flow cytometry | Phosphorylation | Bone marrow | Kinases | Gene expression | Experiments | Cancer therapies | Patients | Pharmaceuticals | Cancer | Index Medicus
Journal Article
15.